We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck presented data at the American Heart Association's Scientific Sessions 2006 showing that coadministration of MK-0524, an investigational DP1-receptor antagonist, with extended-release niacin (ERN) significantly reduced flushing in patients with dyslipidemia compared with those patients who took ERN alone.
Roche has presented the results from two Phase III studies and one Phase II study that showed treatment with the investigational agent tocilizumab -- marketed as Actemra in Japan for Castleman's disease -- consistently improved remission rates in patients with rheumatoid arthritis (RA) compared with placebo or other conventional antirheumatic treatments including the current standard of care, methotrexate.
Exelixis announced that its licensee Helsinn Healthcare has discontinued enrollment of new patients in the becatecarin (XL119) Phase III clinical trial program in biliary tract tumors.
Pharmos announced it has completed its initial analysis of data from a recently completed Phase 1 study of its proprietary NanoEmulsion topical drug-delivery technology formulated with diclofenac.
Alba Therapeutics has presented data showing that when AT- 1001, an investigational oral zonulin receptor antagonist being developed for treatment of celiac disease (CD), was assessed in a double-blind, placebo-controlled study of CD patients, the product induced a positive result on the trial's primary endpoint, intestinal permeability.
CuraGen Cand TopoTarget have announced the initiation of patient dosing in a Phase II clinical trial evaluating the antitumor activity of intravenous PXD101, a small-molecule histone deacetylase (HDAC) inhibitor, for the treatment of ovarian cancer.